Q-omics provides the consensus-scored SP140L profile across patient tissues and cancer cell-line models. SP140L expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, SP140L is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, SP140L RNA expression shows 19,087 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight KIRP, HNSC, and DLBC as cancer lineages where SP140L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SP140L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SP140L survival associations across molecular data types. SP140L RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SP140L RNA expression–survival associations across cancer types. High SP140L expression shows unfavorable associations in KIRP, LGG, LIHC and UCEC, but favorable associations in SKCM and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for SP140L RNA expression.
This table summarizes SP140L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SP140L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SP140L shows lower tumor expression in UCEC and higher tumor expression in HNSC, KIRC, STAD, LIHC and KIRP. The HNSC box plot shows higher SP140L RNA expression in tumor versus normal tissue (log2 FC = +1.308, t-test p < 0.001).
This table shows molecular features associated with SP140L in patient tissues and cancer cell lines. In patient samples, SP140L shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, SP140L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
